Rocin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rocin

What is Rocin? (Clarithromycin Overview)

Property Description
Active Ingredient Clarithromycin
Form Tablets (immediate- and extended-release), Oral Suspension, IV Solution
Pharmacological Class Macrolide Antibiotic
General Purpose To fight infections caused by susceptible bacteria
Origin Semisynthetic (derived from Erythromycin)

What Type of Medicine is Rocin? (Identity and Classification)

Rocin is a prescription-only medication whose sole active ingredient is Clarithromycin, which is officially classified as a macrolide antibiotic. This medicine belongs to the broader group of anti-infective agents used to manage bacterial illnesses. Clarithromycin is recognized as a semisynthetic derivative of the older antibiotic erythromycin. This specific chemical modification was designed to give the compound improved acid stability, a feature clinically recognized for supporting more reliable absorption in the digestive system compared to its parent compound, thereby enhancing its efficacy. This classification is vital for therapeutic decisions.

Composition and Available Forms (Structure and Presentation)

The foundation of the Rocin product is its single active ingredient formulation, consisting solely of Clarithromycin combined with essential pharmaceutical excipients. This design provides a reliable vehicle for the drug's action.

To accommodate diverse patient needs, Clarithromycin is presented in various dosage form(s), including standard immediate-release tablet and the extended-release tablet versions. Liquid formats, such as powder for oral suspension, are also commonly available, allowing for oral administration in patient groups who may have difficulty swallowing solid forms. This range of delivery systems ensures flexible application across the general patient population.

What is the General Purpose of Clarithromycin? (High-Level Benefit)

The general purpose of Clarithromycin is to help the body overcome and eliminate the bacterial pathogens responsible for certain illnesses, such as typical respiratory tract infections. It achieves this by functioning as an antibiotic that specifically targets and interferes with the growth processes of susceptible microorganisms.

Macrolides like Clarithromycin suppress the bacteria's ability to multiply and grow by inhibiting essential protein synthesis. This controlled antimicrobial action is medically relied upon to facilitate the body's recovery from bacterial illnesses.

Regulatory References

  1. Clarithromycin - MeSH - NCBI
  2. Macrolide Antibiotics - Mechanism of Action - NIH

What side effects are possible with Rocin?

Possible Side Effects and Safety Information

The assessment of possible side effects associated with Rocin (Clarithromycin) is based on classifications defined in official government regulatory documents, which categorize reactions by frequency and organ system. The majority of reported effects are classed as Common (occurring in ge 1/100 to < 1/10 patients) and primarily involve the Gastrointestinal and Nervous Systems.

Commonly Documented Adverse Reactions

System-Organ Class Examples
Gastrointestinal Disorders Diarrhea, Nausea, Vomiting, Abdominal pain
Nervous System Disorders Headache, Taste perversion (Dysgeusia)
Hepatobiliary Disorders Abnormal liver function tests

Serious adverse reactions are specifically noted in official labeling. These are often classified as having a Not Known frequency (identified post-marketing). Key concerns include Cardiac Disorders such as QT interval prolongation and the risk of Ventricular Tachycardia (Torsades de Pointes). Severe Hepatic Dysfunction, including rare cases of fatal hepatic failure, and serious skin conditions like Stevens-Johnson syndrome (SJS) are also documented safety concerns. Another serious gastrointestinal event is Clostridium difficile-associated diarrhea (CDAD), which may occur during or months after treatment.

Safety statements also define specific constraints for use. The medicine is contraindicated in patients with a history of QT prolongation or pre-existing Ventricular Arrhythmia. Furthermore, official documents note that the risk of adverse hepatic events is recognized as increased in individuals with hepatic impairment. The safety of use during pregnancy has not been established.

Overdose and Emergency Response

The official regulatory documentation defines the pattern of overexposure to Rocin (Clarithromycin) primarily by pronounced gastrointestinal distress. Documented overdose manifestations include severe stomach pain, nausea, vomiting, and diarrhea, along with generalized abdominal discomfort. High-dose exposure has also been formally associated with the occurrence of transient hearing loss.

Severe or life-threatening manifestations necessitate immediate medical attention. Regulatory guidance states that overexposure carries the risk of serious cardiac arrhythmias, specifically citing QT prolongation and the potential for the severe rhythm disturbance known as Torsades de pointes. Cases of altered mental status have also been documented as a serious outcome.

Emergency action is mandated when symptoms escalate. Individuals exhibiting collapse, a seizure, severe trouble breathing, or the inability to be awakened require that emergency services be contacted immediately, as stipulated by official government sources.

Management of overdose is based on providing symptomatic and supportive treatment; no specific antidote is known. Regulatory information confirms that Rocin is not effectively removed from the body by standard procedures such as hemodialysis or peritoneal dialysis. Due to cardiac risk, clinical monitoring, including ECG monitoring, is recommended. Furthermore, patients with severe renal impairment are noted to be at increased risk of severe manifestations due to reduced drug clearance.

Therapeutic Uses of Rocin

Rocin is commonly used to help manage distressing symptoms caused by susceptible bacterial infections, applied across domains where additional symptomatic support is needed. This medication is relevant for easing symptoms associated with illnesses like Community-Acquired Pneumonia, Acute Bronchitis exacerbations, sinus and ear infections, and specific skin and soft tissue infections. It may also be part of symptomatic management within multi-drug therapy for Peptic Ulcer Disease and Disseminated MAC infections.

The primary therapeutic purpose is to address conditions involving symptoms related to systemic imbalance, which may help manage symptoms that interfere with daily functioning and create noticeable physiological strain.

“Its application is relevant when supportive symptom management is appropriate, helping patients cope more steadily with difficult episodes.”


Quick Fact: Supportive Management for Acute Symptoms

Rocin is relevant in contexts involving heightened systemic burden and symptoms associated with acute or episodic changes, providing support that helps ease the overall symptom burden associated with bacterial respiratory, skin, and ENT conditions. It assists with supporting functional stability when symptoms become more disruptive during flare-ups.

Regulatory References

  1. DailyMed official label

Eligibility and Restrictions for Use

The official regulatory documentation for Rocin (Clarithromycin) strictly defines the population groups who are eligible or absolutely prohibited from using the medicine. This eligibility profile is structured around specific conditions and physiological states.

Absolute Contraindications

Rocin is contraindicated for patients with a known hypersensitivity or allergy to any macrolide antibiotic. Use is also prohibited in individuals with pre-existing cardiac conditions such as a history of QT prolongation or ventricular arrhythmias, and those with uncorrected hypokalemia or hypomagnesemia. Furthermore, the medicine must not be used if a patient has severe hepatic failure combined with renal impairment. The concurrent use of certain drugs, including simvastatin, lovastatin, and ergot alkaloids, is also an absolute contraindication specified in official labeling.


Restricted and Age-Group Eligibility

The medicine is permitted for adults and pediatric patients typically 6 months of age and older. However, use for the film-coated or extended-release tablets is generally not recommended for children under 12 years. Regarding physiological states, the medicine is not recommended for use during pregnancy or while breastfeeding, as clarithromycin is excreted into human milk. Specific caution is required for patients with severe renal impairment or mild-to-moderate hepatic dysfunction.

What should I know about interactions with other medicines?

Rocin (Clarithromycin) interactions are primarily governed by its officially documented function as a potent inhibitor of the CYP3A4 metabolic enzyme and the P-glycoprotein transporter. This established enzymatic and transporter inhibition can lead to significantly increased systemic exposure of co-administered medicinal products, which forms the basis for numerous regulatory restrictions.

Officially Contraindicated Combinations

Based on government regulatory documentation, Rocin is strictly prohibited for co-administration with several agents. These contraindicated combinations include Pimozide and Cisapride, due to the documented risk of serious cardiac arrhythmias. Also prohibited are Lovastatin and Simvastatin, as co-use increases the risk of muscle toxicity, including rhabdomyolysis. The combination with Ergot Alkaloids (Ergotamine and Dihydroergotamine) is prohibited due to the documented risk of vasospasm and resulting ischemia.

Administration and Condition Constraints

  • Population Specificity: Co-administration with Colchicine is explicitly contraindicated only in patients with existing renal or hepatic impairment.
  • Food Requirement: The extended-release tablet formulation must be taken with food to ensure its intended pharmacokinetic profile, as stated in regulatory instructions.
  • Timing Rule: Administration with the antiretroviral drug Zidovudine requires a minimum of two hours separation to avoid altering Zidovudine's absorption.
  • Pharmacodynamic Risk: Regulatory documents warn of an additive risk of QT prolongation when Rocin is combined with other QTc-prolonging medicinal products.

Mechanism of Action

Disruption of Bacterial Protein Synthesis

The primary mechanism of action targets the core machinery of the pathogen, specifically by binding to the 23S ribosomal RNA within the 50S ribosomal subunit . This precise engagement physically inhibits polypeptide chain elongation, rapidly halting the synthesis of essential structural and functional proteins. The primary physiological consequence is a bacteriostatic effect that acts to suppress the growth and multiplication of susceptible bacterial cells.


Constraints and Failure of the Mechanism

The drug's action is fundamentally constrained by specific bacterial counter-mechanisms, such as the enzymatic methylation of the ribosomal target site or the active expulsion of the drug via efflux pumps. When these biological defenses are present, they prevent the molecule from achieving effective ribosomal binding, which functionally overrides the inhibitory cascade. The mechanism is also inherently irrelevant against pathogens lacking the specific prokaryotic 50S ribosomal subunit.


Auxiliary Modulation of Host Immune Response

Clarithromycin exerts a secondary, non-antimicrobial effect by acting as a modulator of host inflammatory pathways. This involves influencing the cellular release and balance of key signaling molecules, such as cytokines. This auxiliary action contributes to the modulation of inflammatory pathway activity, which is a secondary physiological consequence separate from the primary effect of pathogen suppression.

Dosage and Administration Information

The administration of Rocin (Clarithromycin) is governed by strict, form-dependent instructions documented in prescribing information. The medicine is primarily utilized via the oral route using immediate-release (IR) or extended-release (ER) tablets, in addition to an oral suspension. For patients requiring parenteral care, an intravenous infusion route is also officially documented for use.


Dosing and Frequency Patterns

The standard adult regimen for the immediate-release form is 250 mg to 500 mg taken twice daily (every 12 hours). The extended-release form follows a simpler schedule of 1000 mg administered once daily. For children, the regimen relies on the oral suspension and is calculated based on body weight, typically 7.5 mg/kg twice daily. The typical duration of a treatment course for acute infections ranges from 6 to 14 days, though specific chronic conditions may require continuous, long-term administration.


Administration Conditions

Specific procedural constraints apply based on the chosen form. The Extended-Release (XL) tablets must be administered with food and must be swallowed whole without crushing, chewing, or breaking them. The standard immediate-release forms may be taken without regard to meals. A major procedural modification applies to patients with severe renal impairment (creatinine clearance < 30 mL/min), for whom the total daily dose is officially reduced by one-half. Tablets are generally not recommended for children under 12 years of age.

Recent Clinical Evidence

Rocin: Overview of Studies

This overview summarizes the structure of clinical research for Rocin (Clarithromycin), describing group patterns observed in studies without offering advice, dosing, or safety instructions.

Evidence for Use in Acute Infections

Rocin was evaluated in short-term Randomized Controlled Trials (RCTs) and observational studies for conditions like Community-Acquired Pneumonia (CAP) and Acute Bronchitis exacerbations, which are conditions involving periods of heightened symptoms. These studies included adults and adolescents and monitored outcomes related to patient status and microbiological clearance. Findings describe patterns related to measured short-term outcomes when Rocin was studied for use alongside other concurrent treatments. However, evidence quality varies across studies regarding long-term outcomes such as 90-day mortality.

For H. pylori-related Peptic Ulcer Disease, Rocin was observed in multi-drug regimens. Research examined bacterial eradication rates and ulcer healing. The outcomes of these combination regimens appears to be highly dependent on the baseline clarithromycin resistance rate in a given area, and comparative evidence is lacking that isolates the contribution of Rocin alone.

Research into Long-Term Outcomes

Beyond the immediate treatment phase, Rocin was studied for its potential long-term follow-up effects in large-scale RCTs and Observational Studies, tracking patients for up to 10 years. The main outcomes examined were all-cause mortality and cardiovascular-related mortality. One key RCT, focusing specifically on a subgroup of patients with stable Coronary Heart Disease (CHD), reported an observed pattern related to mortality years after the treatment ended. Conversely, subsequent observational studies have produced mixed findings.

Long-term effects are not fully established for the general population. The late-emerging pattern observed in the CHD group appears to be unestablished by an underlying biological explanation, and there is limited information for long-term outcomes from dedicated prospective studies.

Key Studies & References

  1. Label: CLARITHROMYCIN tablet - DailyMed (Official FDA Label for Immediate Release Formulations)
  2. Disseminated Mycobacterium avium Complex: Adult and Adolescent OIs (Treatment Guidelines referencing Clarithromycin combination therapy)

Frequently Asked Questions (FAQ)

Common questions about Rocin (FAQ)


Q: What is the main medical condition Rocin is used to treat?

According to official product information, Rocin is indicated for treating mild to moderate infections caused by susceptible bacteria. These approved uses include infections of the upper and lower respiratory tract, such as acute sinusitis and community-acquired pneumonia, as well as skin and soft tissue infections. It is also used as part of a multi-drug regimen to eliminate H. pylori, a bacterium often associated with peptic ulcers.


Q: Are there any reported serious or severe allergic reactions linked to Rocin?

Serious allergic reactions, including anaphylaxis, are possible with this medication. Official documents describe signs of a serious reaction, which may include swelling of the face, tongue, or throat, and difficulty breathing.


Q: What other prescription medications are known to interact with Rocin?

Rocin is described as a potent inhibitor of the CYP3A4 metabolic enzyme. This enzymatic and transporter inhibition can lead to significantly increased systemic levels of many co-administered medicines that rely on this pathway for breakdown. For this reason, official product information includes numerous warnings regarding co-administration with other prescription drugs.


Q: Can children take Rocin, and are there special considerations?

Official documents permit the use of Rocin for pediatric patients typically 6 months of age and older. It is usually administered in the oral suspension form, with the quantity determined by a healthcare professional based on official guidelines. The tablet forms are generally not recommended for children under 12 years of age.


Q: Is a history of liver problems a factor that prevents the use of Rocin?

Rocin is strictly prohibited for use in patients who have severe hepatic failure (a serious form of liver damage) combined with renal impairment (kidney damage). The medication is also contraindicated for those with a history of cholestatic jaundice or liver dysfunction associated with previous use of the drug. Official documents indicate that specific caution is required for use in patients with impaired liver function.


Q: How is Rocin different from other common antibiotics like amoxicillin or penicillin?

Rocin belongs to the macrolide class of antibiotics, whereas penicillin and amoxicillin are in the penicillin class. Official guidance recognizes Rocin as an alternative therapeutic option for certain infections in individuals who have a known hypersensitivity (allergy) to penicillin-class drugs.


Q: Can Rocin be prescribed for uses other than bacterial infections?

Official regulatory documents specify that Rocin is intended for use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. The mechanism of action is focused exclusively on targeting specific microbial structures.


Q: Is Rocin considered a 'strong' or powerful antibiotic?

Rocin is officially classified as a macrolide antibiotic. Its fundamental purpose, as described in regulatory documents, is to interfere with the growth of susceptible bacteria by inhibiting the synthesis of essential proteins. This classification guides its therapeutic use against certain types of infections.


Q: Are there any specific tests, like blood or kidney function tests, recommended while taking Rocin?

Official documentation notes that abnormal liver function tests are a commonly reported adverse effect. In specific circumstances, such as when Rocin is combined with drugs that can cause hearing or balance issues (ototoxic drugs), the official label notes that monitoring of vestibular and auditory function may be relevant.


Q: How long after starting Rocin should a person expect to see improvement in their symptoms?

Guidance notes that patients will likely begin to feel better soon after starting treatment with Rocin. However, it is stated that it generally takes a few days for the medication to eliminate the bacteria. Official guidance emphasizes the importance of completing the full course of medication as directed, even if symptoms begin to improve early.


Q: Is it necessary to avoid alcohol completely while taking Rocin?

Official regulatory documents do not list an absolute prohibition on alcohol use with Rocin. However, advice for managing common side effects like headache does include the recommendation to avoid drinking too much alcohol.


Q: Are there any specific safety concerns for older patients using Rocin?

Official product information indicates that the general dosage for older patients is the same as for adults. However, dosage adjustments are a consideration if an older patient is also identified as having severe renal impairment (significant kidney problems).


Q: Why is Rocin sometimes prescribed for a shorter duration than other antibiotics?

The exact duration of treatment with Rocin is determined by the specific type of infection being treated, typically varying from 6 to 14 days. The drug's active metabolite (14-OH clarithromycin) has a longer elimination half-life, which influences and supports its prescribed dosing schedule.


Q: What does it mean that Rocin has a 'long half-life'?

The half-life refers to the time it takes for half of the drug to be eliminated from the body. Regulatory documents describe the elimination half-life of Rocin as being approximately 3 to 7 hours, with variations noted in official studies. Its active metabolite has a longer half-life, reported to be around 7 to 9 hours.


Q: What are the common signs that Rocin may not be working to treat the infection?

Official guidance states that a lack of improvement in symptoms within a few days, or if symptoms become worse, are factors that indicate consultation with a healthcare professional. These signs may suggest the infection is not responding as expected.


Q: What should a person do if they miss a scheduled dose of Rocin?

Official instructions describe the procedure for a missed dose: it may be taken as soon as remembered, unless it is almost time for the next scheduled dose. If that is the case, the missed dose should be skipped, and the regular schedule continued. The established procedure cautions against taking a double dose to compensate for a missed one.


Q: What are the risks if Rocin is taken at a higher amount than prescribed?

Symptoms reported in cases of overdose may include stomach pain, nausea, vomiting, and diarrhea. Official guidance emphasizes that symptoms of overdose are a serious concern requiring immediate attention from emergency services or a healthcare professional.


Q: Is it normal to feel tired or weak while taking Rocin?

Extreme tiredness, described as fatigue, has been listed in official safety information as a possible side effect of Rocin. This is a potential effect that patients may experience during treatment.


Q: Does Rocin interact with common vitamins or dietary supplements?

Official guidance notes that Rocin may not mix well with some complementary and herbal remedies. Official guidance highlights that consultation with a healthcare professional is necessary before combining Rocin with any herbal remedies or supplements.


Q: What safety precautions are typically recommended for patients with Myasthenia Gravis who are prescribed Rocin?

Official safety information notes that the use of Rocin in patients who have myasthenia gravis, a condition that causes muscle weakness, requires caution. The medication may worsen the symptoms of this pre-existing condition.


Q: Can Rocin cause dizziness or affect a person's balance?

Official safety information reports that Rocin may cause certain nervous system effects. These reported effects include dizziness, confusion, and disorientation.

How should Rocin be stored and disposed of?

The storage and disposal instructions for Rocin (Clarithromycin) are defined by official regulatory labeling to ensure product stability and safety.

Storage Conditions

Product Form Required Environment Stability Constraint
Tablets / Dry Granules Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) [DailyMed] Must be protected from excessive moisture [FDA].
Reconstituted Suspension Store at Room Temperature (up to 30 C); Do not refrigerate [MedlinePlus] Stable for only 14 days; must be discarded thereafter [DailyMed].

All forms must be kept in their original container, which should be tightly closed [MedlinePlus]. For safety, the medicine must be stored out of the sight and reach of children [MedlinePlus].

Disposal Instructions

Unused or expired medication should be disposed of using a drug take-back program where available [FDA]. If no take-back option is accessible, the medicine must be mixed with an undesirable substance (e.g., dirt, cat litter) and sealed in a container for disposal in the household trash [FDA]. All personal identifying information should be scratched out on the packaging before discarding [FDA].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rocin found in:

A-Z Index: